Weight Loss for Women After 45, Built Around the Transition

Everyone who joins the ACT 2 weight program begins with a baseline panel. For a woman after 45, the reading is deliberately wider than a metabolic screen.

The metabolic side: fasting glucose and insulin, A1c, the full lipid panel, liver and kidney function, and inflammatory markers. These show whether insulin resistance or prediabetes is part of the picture, which changes which medication is considered and how progress is judged.

The hormone side: estradiol and FSH, read against your cycle history and symptoms rather than as isolated numbers; thyroid function, including TSH and free T4; a morning cortisol where sleep and stress are part of the story; ferritin and vitamin D; and, where relevant, testosterone and SHBG.

Two deserve a sentence each. Thyroid, because an underactive thyroid produces weight gain, fatigue and cold intolerance that overlap almost perfectly with perimenopause, and MedlinePlus is clear that it is diagnosed by blood test, not by symptoms. And cortisol, because a woman whose nights are broken by hot flashes is running a stress physiology that drives appetite and abdominal fat storage, and no appetite medication fixes a sleep problem.

No single value is a verdict. The clinician reads the panel as a whole, against how you actually feel.

The Menopause Society's hormone therapy position statement describes hormone therapy as the most effective treatment for hot flashes and night sweats and as effective at preventing bone loss, with the most favorable balance of benefit and risk for women who begin it before 60 or within ten years of their final period. It does not describe hormone therapy as a weight-loss treatment, and neither do we. Whether HRT adds or removes weight is covered on does HRT cause weight gain and losing weight on HRT.

Hormone therapy comes first when the symptoms of the transition are the thing in the way. A woman with broken sleep, hot flashes and a shifted mood cannot train, eat consistently or recover, and starting a GLP-1 into that picture asks the medication to do work it was not designed for. Hormone therapy for women treats the symptoms first; weight is reassessed once sleep and energy settle.

The two run alongside each other when a woman has both clear menopause symptoms and weight that has not responded to lifestyle change. The sequence is still deliberate: the prescribing clinician reviews the labs each treatment depends on, and the program is adjusted as the hormone picture changes.

A GLP-1 alone fits a woman who is past the transition or whose symptoms are mild, whose thyroid and other markers are in order, and whose weight meets the clinical criteria for medication. The two options at ACT 2 are semaglutide and tirzepatide, both prepared by a licensed compounding pharmacy. They are not FDA-approved and are not the same as, equivalent to, or interchangeable with any branded medication. Which one is appropriate is a clinical decision, not a menu choice.

In every version the GLP-1 is the smaller part of the plan. NIDDK's guidance is that weight-management medication works alongside changes in eating and activity, not in place of them.

For a woman after menopause, this matters more than the choice of medication.

Weight loss takes some lean tissue with the fat unless lean tissue is actively defended, and a woman entering the program has already been losing muscle through the transition. The clinical name for that trajectory is sarcopenia; the practical consequence is a smaller number on the scale with a weaker body underneath it.

Bone is the second concern. The Endocrine Society describes the drop in estrogen at menopause as the point at which bone loss accelerates, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) lists being a woman past menopause among the main risk factors for osteoporosis. Rapid weight loss adds to that pressure, and a suppressed appetite makes it easy to under-eat protein and calcium without noticing.

So the program defends both, deliberately:

• Protein comes first at every meal. With appetite suppressed, protein is what gets displaced, so it is planned rather than left to chance. The clinician sets a target that fits you.
• Resistance training is not optional. Walking is excellent for the heart and does little for muscle or bone. Progressive strength work is the signal that tells both tissues to stay.
• Progress is judged on composition, not the scale alone. Waist, strength and how clothes fit are tracked alongside weight. A fast drop with falling strength is a reason to slow down, not a success.
• Bone is watched, not assumed. Where the history warrants it, the clinician will recommend a bone density scan. We do not perform imaging, so that is a referral, and we will say so plainly.

If weight is coming off but the shape is not changing as expected, see muscle loss versus fat gain.

Month one is measurement and a decision: the online assessment, the baseline panel, and a video visit where the clinician reviews the labs any treatment depends on and settles the plan — hormone therapy first, a GLP-1 first, or both. Medication, if prescribed, is delivered to your home.

Month two is adjustment: tolerance, appetite, sleep and training are checked. This is when under-eating protein becomes a risk, so it is the month we ask most about meals.

Month three is the first real read: labs that need repeating are repeated, composition is reviewed against baseline, and the question is asked directly — is this working on the things you came in for, and is the body underneath getting stronger or weaker? The plan changes if the answer is wrong.

Each program includes a live visit with a licensed clinician and, where medication is prescribed, home delivery with no separate medication fee. Everything is a subscription you can cancel at any time.

• Semaglutide: $299 a month, or $550 for a two-month package, which works out to $275 a month. Full cost breakdown.
• Tirzepatide: $399 a month, which is more than semaglutide. Whether the difference is worth paying is a clinical conversation.
• Hormone therapy for women: $349 for the first month, which includes the baseline lab panel, then $99 a month after that.
• Comprehensive lab panel on its own: $199, one time, for a woman who wants the data before deciding anything.

The new-patient offer on either GLP-1: $100 off your first month for new patients. The 10% welcome code applies elsewhere on the site but cannot be combined with that offer.

It suits a woman after 45 whose weight has stopped responding to what used to work, who wants the hormone picture read before anything is prescribed, and who will treat protein and strength training as part of the prescription. It suits a woman already on hormone therapy whose weight has not moved, and a woman who tried a GLP-1 elsewhere and did not like how she felt or looked at the end of it.

It does not suit a woman who wants the medication without the measurement. We do not prescribe a GLP-1 on a questionnaire alone, and the labs are not a formality to be skipped.

Some of the most useful conversations in this program end without a GLP-1 prescription.

• An untreated or under-treated thyroid. Thyroid dysfunction on the panel is treated first and weight is reassessed afterward. Suppressing appetite on top of an underactive thyroid treats the wrong problem.
• A history of disordered eating. Appetite-suppressing medication can revive restrictive patterns. We will say so and refer rather than prescribe.
• Pregnancy, trying to conceive or breastfeeding. NIDDK is explicit that weight-management medication is not for women who are pregnant or breastfeeding, and a woman in late perimenopause can still conceive.
• Weight that is normal but a shape that has changed. A GLP-1 is not a treatment for fat that has moved to the middle at an unchanged weight. That presentation has a different explanation and plan. More on menopause belly.
• Symptoms that are really the menopause. If sleep, mood and hot flashes are the complaint and weight is the symptom, start with menopause and perimenopause, not here.